Literature DB >> 10580838

Transcription control and neuronal differentiation by agents that activate the LXR nuclear receptor family.

A Schmidt1, R Vogel, M K Holloway, S J Rutledge, O Friedman, Z Yang, G A Rodan, E Friedman.   

Abstract

LXR and PPAR receptors belong to the nuclear receptor superfamily of transcriptional activating factors. Using ligand-dependent transcription assays, we found that 5-tetradecyloxy-2-furancarboxylic acid (TOFA) transactivates chimeric receptors composed of the glucocorticoid receptor DNA binding domain and the ligand binding regions of PPARalpha, PPARbeta (NUC-1) and LXRbeta (NER) receptors. In the same assays, ligands for PPARs (oleic acid, WY-14643 and L-631,033) and LXRs (hydroxycholesterols) maintain their respective receptor selectivity. TOFA and hydroxycholesterols also stimulate transcription from a minimal fibrinogen promoter that is under the control of AP-1 or NF-kappaB transcription factor binding sites. In addition to their effects on transcription, these LXRbeta activators induce neuronal differentiation in rat pheochromocytoma cells. TOFA and the natural LXR agonist, 22 (R)-hydroxycholesterol, stimulate neurite outgrowth in 55 and 28% of cells, respectively. No neurite outgrowth was induced by the related 22(S)-hydroxycholesterol, which does not activate the LXR family. These results suggest that the hydroxycholesterol signaling pathway has a complex effect on transcription that mediates the activity of TOFA and hydroxycholesterol on neuronal differentiation in pheochromocytoma cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580838     DOI: 10.1016/s0303-7207(99)00115-x

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  8 in total

1.  The neurorestorative benefit of GW3965 treatment of stroke in mice.

Authors:  Xu Cui; Michael Chopp; Alex Zacharek; Yisheng Cui; Cynthia Roberts; Jieli Chen
Journal:  Stroke       Date:  2012-11-29       Impact factor: 7.914

2.  Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration.

Authors:  Ling Wang; Gertrud U Schuster; Kjell Hultenby; Qinghong Zhang; Sandra Andersson; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-04       Impact factor: 11.205

3.  Peroxisome proliferator-activated receptor agonists prevent 25-OH-cholesterol induced c-jun activation and cell death.

Authors:  J Y Chang; L Z Liu
Journal:  BMC Pharmacol       Date:  2001-11-27

Review 4.  Targeting cholesterol homeostasis to fight hearing loss: a new perspective.

Authors:  Brigitte Malgrange; Isabel Varela-Nieto; Philippe de Medina; Michael R Paillasse
Journal:  Front Aging Neurosci       Date:  2015-01-29       Impact factor: 5.750

5.  Cross-talk between oxysterols and glucocorticoids: differential regulation of secreted phopholipase A2 and impact on oligodendrocyte death.

Authors:  Amalia Trousson; Joelle Makoukji; Patrice X Petit; Sophie Bernard; Christian Slomianny; Michael Schumacher; Charbel Massaad
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

6.  Inhibitors of Fatty Acid Synthesis Induce PPAR α -Regulated Fatty Acid β -Oxidative Genes: Synergistic Roles of L-FABP and Glucose.

Authors:  Huan Huang; Avery L McIntosh; Gregory G Martin; Anca D Petrescu; Kerstin K Landrock; Danilo Landrock; Ann B Kier; Friedhelm Schroeder
Journal:  PPAR Res       Date:  2013-02-26       Impact factor: 4.964

7.  Oleoylethanolamide and Palmitoylethanolamide Protect Cultured Cortical Neurons Against Hypoxia.

Authors:  Manuel Portavella; Nieves Rodriguez-Espinosa; Pablo Galeano; Eduardo Blanco; Juan I Romero; Mariana I Holubiec; Fernando Rodriguez de Fonseca; Emilio Fernández-Espejo
Journal:  Cannabis Cannabinoid Res       Date:  2018-09-19

8.  Treatment of stroke with a synthetic liver X receptor agonist, TO901317, promotes synaptic plasticity and axonal regeneration in mice.

Authors:  Jieli Chen; Alex Zacharek; Xu Cui; Amjad Shehadah; Hao Jiang; Cynthia Roberts; Mei Lu; Michael Chopp
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-02       Impact factor: 6.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.